Skip to main content
SpringerLink
Log in

Cost of new cancer drug too high for Memorial Sloan-Kettering

  • Comment
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cost of new cancer drug too high for Memorial Sloan-Kettering. Pharmacoecon. Outcomes News 665, 2 (2012). https://doi.org/10.2165/00151234-201206650-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-201206650-00003

Keywords

Search

Navigation